Table 1.
Demographic characteristics.
| Dementia (N = 1,621) | Non-dementia (N = 1,621) | ||||
|---|---|---|---|---|---|
| n | % | n | % | p-value | |
| Age | 1 | ||||
| 50–64 | 104 | 6.4 | 104 | 6.4 | |
| 65–79 | 920 | 56.8 | 920 | 56.8 | |
| ≥80 | 597 | 36.8 | 597 | 36.8 | |
| Mean ± SD | 76.9 ± 7.1 | 76.9 ± 7.1 | 1 | ||
| Gender | 1 | ||||
| Female | 651 | 40.2 | 651 | 40.2 | |
| Male | 970 | 59.8 | 970 | 59.8 | |
| Hypertension | 1375 | 84.8 | 1272 | 78.5 | <0.001 |
| Hyperlipidemia | 689 | 42.5 | 672 | 41.5 | 0.545 |
| Chronic liver disease | 332 | 20.5 | 302 | 18.6 | 0.184 |
| Chronic kidney disease | 223 | 13.8 | 171 | 10.5 | 0.005 |
| Diabetes | 638 | 39.4 | 538 | 33.2 | <0.001 |
| COPD | 516 | 31.8 | 411 | 25.4 | <0.001 |
| Autoimmune disease | 62 | 3.8 | 50 | 3.1 | 0.248 |
| Cardiovascular disease | 670 | 41.3 | 601 | 37.1 | 0.013 |
| Stroke | 760 | 46.9 | 357 | 22.0 | <0.001 |
| Depression | 285 | 17.6 | 75 | 4.6 | <0.001 |
| Parkinson's disease | 195 | 12.0 | 51 | 3.1 | <0.001 |
| Allopurinol | 476 | 29.4 | 438 | 27.0 | 0.138 |
| Benzbromarone | 1,195 | 73.7 | 1,256 | 77.5 | 0.013 |
| Sulfinpyrazone | 72 | 4.4 | 64 | 3.9 | 0.483 |
| Probenecid | 18 | 1.1 | 10 | 0.6 | 0.129 |
| Warfarin | 96 | 5.9 | 65 | 4.0 | 0.012 |
| Statin | 631 | 38.9 | 591 | 36.5 | 0.147 |
| Gout year | 1 | ||||
| 2000 | 539 | 33.3 | 539 | 33.3 | |
| 2001 | 328 | 20.2 | 328 | 20.2 | |
| 2002 | 247 | 15.2 | 247 | 15.2 | |
| 2003 | 178 | 11.0 | 178 | 11.0 | |
| 2004 | 124 | 7.6 | 124 | 7.6 | |
| 2005 | 90 | 5.6 | 90 | 5.6 | |
| 2006 | 61 | 3.8 | 61 | 3.8 | |
| 2007 | 36 | 2.2 | 36 | 2.2 | |
| 2008 | 18 | 1.1 | 18 | 1.1 | |
| Study period (years) | 7.8 ± 2.4 | 7.8 ± 2.4 | 0.917 | ||
COPD, Chronic obstructive pulmonary disease.